- £198.21bn
- £217.54bn
- $54.07bn
- 85
- 16
- 86
- 71
REG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Lynparza granted FDA Priority Review for OlympiA
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - AZN: Year to date and Q3 2021 results
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca to transfer rights to Eklira, Duaklir
AnnouncementREG - AstraZeneca PLC - Imfinzi improved survival in biliary tract cancer
AnnouncementREG - AstraZeneca PLC - AZ recommends ADS holders reject mini-tender offer
AnnouncementREG - AstraZeneca PLC - Imfinzi & tremelimumab improved OS in liver cancer
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - AZD7442 PhIII trial positive in COVID outpatients
AnnouncementREG - AstraZeneca PLC - Enhertu granted BTD for breast cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - AstraZeneca to fully acquire Caelum Biosciences
AnnouncementREG - AstraZeneca PLC - Saphnelo approved in Japan for SLE
AnnouncementREG - AstraZeneca PLC - Lynparza PROpel trial meets primary endpoint
Announcement